Reply to correspondence on “Comparison of glucagonlike peptide-1 receptor agonists and thiazolidinediones on treating nonalcoholic fatty liver disease: a network meta-analysis”

키워드

참고문헌 (15)

1. Ren TY, "Incretin-based therapy in the management of metabolic dysfunction-associated steatotic liver disease(MASLD) : one piece of the puzzle : Editorial on"Comparison of glucagon-like peptide-1 receptor agonists and thiazolidinediones on treating nonalcoholic fatty liver disease : A network meta-analysis"", Clin Mol Hepatol, 30, pp.649~652 (2024)
2. Kim H, "Correspondence to editorial on"Comparison of glucagon-like peptide-1 receptor agonists and thiazolidinediones on treating nonalcoholic fatty liver disease : a network meta-analysis"", Clin Mol Hepatol, 30, pp.989~991 (2024)
3. Le MH, "Global incidence of adverse clinical events in non-alcoholic fatty liver disease : a systematic review and meta-analysis", Clin Mol Hepatol, 30, pp.235~246 (2024)
4. Nakatsuka T, "Development and prognosis of hepatocellular carcinoma in patients with diabetes", Clin Mol Hepatol, 29, pp.51~64 (2023)
5. Kim KS, "Beneficial effect of anti-diabetic drugs for nonalcoholic fatty liver disease", Clin Mol Hepatol, 26, pp.430~443 (2020)
6. Park MJ, "Comparison of glucagon-like peptide-1 receptor agonists and thiazolidinediones on treating nonalcoholic fatty liver disease : a network meta-analysis", Clin Mol Hepatol, 29, pp.693~704 (2023)
7. Qu Y, "Diagnostic accuracy of hepatic proton density fat fraction measured by magnetic resonance imaging for the evaluation of liver steatosis with histology as reference standard : a meta-analysis", Eur Radiol, 29, pp.5180~5189 (2019)
8. Petroff D, "Assessment of hepatic steatosis by controlled attenuation parameter using the M and XL probes : an individual patient data meta-analysis", Lancet Gastroenterol Hepatol, 6, pp.185~198 (2021)
9. Castera L, "Prospective head-to-head comparison of non-invasive scores for diagnosis of fibrotic MASH in patients with type 2 diabetes", J Hepatol, 81, pp.195~206 (2024)
10. Zhang S, "Screening strategy for non-alcoholic fatty liver disease", Clin Mol Hepatol, 29(Suppl), pp.S103~S122 (2023)
11. Myers RP, "Controlled Attenuation Parameter(CAP) : a noninvasive method for the detection of hepatic steatosis based on transient elastography", Liver Int, 32, pp.902~910 (2012)
12. Sato-Espinoza K, "Update in lean metabolic dysfunction-associated steatotic liver disease", World J Hepatol, 16, pp.452~464 (2024)
13. Kim HK, "Association of visceral fat obesity, sarcopenia, and myosteatosis with non-alcoholic fatty liver disease without obesity", Clin Mol Hepatol, 29, pp.987~1001 (2023)
14. Locatelli JC, "Incretin-Based Weight Loss Pharmacotherapy : Can Resistance Exercise Optimize Changes in Body Composition?", Diabetes Care, 47, pp.1718~1730 (2024)
15. Nikolic D, "Liraglutide improved cardiometabolic parameters more in obese than in non-obese patients with type 2 diabetes : a real-world 18-month prospective study", Diabetes Ther, 13, pp.453~464 (2022)

관련 논문AI추천